US FDA approves Incyte’s merkel cell carcinoma therapy
Pharmaceutical Technology
MARCH 23, 2023
It is also being assessed in other tumour types and along with other Incyte pipeline compounds. Diarrhoea, rash, pyrexia, nausea, musculoskeletal pain, fatigue and pruritus are the most common adverse reactions observed in patients treated with Zynyz. Partial response was seen in 22 patients and complete response in 12 patients.
Let's personalize your content